<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226446</url>
  </required_header>
  <id_info>
    <org_study_id>2010-021967-34</org_study_id>
    <nct_id>NCT01226446</nct_id>
  </id_info>
  <brief_title>Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders</brief_title>
  <acronym>ANRS VITAVIC</acronym>
  <official_title>Multicenter Open and Prospective Trial Assessing the Efficacy of Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency is commonly found in patients with chronic hepatitis C. The
      investigators hypothesize that the correction of hypovitaminosis D before the initiation of
      anti-HCV combination therapy and the maintenance of an optimal vitamin D status during
      antiviral therapy could improve the antiviral efficacy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, prospective evaluation of the efficacy of vitamin D supplementation starting 1
      month before and continuing for the duration of combination therapy with pegylated interferon
      alpha (2a or 2b) plus ribavirin in patients with chronic viral hepatitis C genotype 1 or 4,
      nonresponders to a first antiviral therapy.Vitamin D supplementation is started one month
      before antiviral therapy in order to introduce pegylated interferon plus ribavirin in
      patients with optimal vitamin D status
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negativity of HCV RNA below 12UI/mL after 12 weeks of antiviral combination therapy</measure>
    <time_frame>at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HCV viral load after correction of vitamin D deficiency (delta log)</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HCV viral load (delta log)</measure>
    <time_frame>at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HCV viral load (delta log)</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negativity of HCV RNA below 12 UI/ml</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negativity of HCV RNA below 12 UI/ml</measure>
    <time_frame>at week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Addition of Vitamin D to Peg-interferon plus Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>Vitamin D on top of the standard treatment</description>
    <arm_group_label>Addition of Vitamin D to Peg-interferon plus Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Hepatitis C Genotype 1 or 4

          -  Hypovitaminosis D defined by a value &lt;30 ng / ml

          -  Patient non responder to previous antiviral combination therapy of Pegylated
             Interferon and Ribavirin defined by a decrease in viral load &lt;2 log at week 12 of the
             first course (Peg/RBV)

          -  Patient who received at least 80% of the optimal dose of Pegylated Interferon and
             Ribavirin according to current recommendations

          -  Patient for which the investigating physician decided to initiate treatment for
             hepatitis C combination therapy

        Exclusion Criteria:

          -  Decompensated liver disease: Child-Pugh B&gt; 8 or one of the following criteria:
             bilirubin&gt; 35 micromol/L, TP &lt;50%, ascites, recurrent encephalopathy

          -  Positive serology for HBV and HIV

          -  Alcohol consumption exceeding 50 g/day

          -  Chronic intake of vitamin D

          -  Thrombocytopenia &lt;50 000/mm ³, neutropenia &lt;750/mm ³, hemoglobin &lt;11 g/dL

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Cacoub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié Salpétrière Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

